Shares in Allergan fell after the company said it had swung to a loss in the last quarter of 2018, and forecast 2019 revenues below analyst expectations.
Pfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to claims for hundreds of millions of pounds from the NHS.
Allergan and Sosei’s experimental Alzheimer’s medicine has run into trouble – the companies have called a halt to trials after an unexpected toxicology finding in an animal study.<